GHRP-2
FitnessAlso known as: Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102, D-Ala-D-βNal-Ala-Trp-D-Phe-Lys-NH₂
Emerging ResearchWhat is GHRP-2?
A second-generation synthetic growth hormone-releasing peptide (GHRP) that mimics ghrelin at the GHSR-1a receptor, triggering GH pulses from the pituitary. More potent than its predecessor GHRP-6 in terms of peak GH output, with meaningfully less appetite stimulation — making it the higher-output option when hunger is a concern. Not FDA-approved; human studies exist but are small.
How it works
Binds the ghrelin receptor (GHSR-1a) in the pituitary gland, triggering growth hormone secretion independently of endogenous GHRH. Also acts on hypothalamic neurons to suppress somatostatin (GH's natural inhibitor), creating a dual-action GH-amplifying mechanism. Unlike its precursor GHRP-6, GHRP-2 produces a stronger and more sustained peak GH pulse, raises cortisol and prolactin to a moderate degree, but stimulates appetite less aggressively — a practically significant difference for users targeting body composition rather than bulk.
What marketers claim
- ▸dramatically increases muscle mass like steroids
- ▸safe and natural growth hormone booster
- ▸replaces HGH injections entirely
- ▸no side effects
What evidence supports
- ✓human studies demonstrate significant dose-dependent GH pulses within 15–30 minutes of injection
- ✓modest increases in cortisol and prolactin confirmed in human pharmacology studies — clinically relevant side effect profile
- ✓more potent GH release than GHRP-6 in head-to-head human comparisons, with less orexigenic (appetite-stimulating) effect
- ✓used clinically in some countries as a diagnostic tool (pralmorelin stimulation test) to assess GH deficiency
- ✓no large-scale human RCTs for body composition or anti-aging outcomes
Research evidence
Key studies on GHRP-2, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.
Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man
Finding: Both GHRP-2 and hexarelin produced significant dose-dependent GH pulses within 15–30 minutes of subcutaneous injection. GHRP-2 also produced modest but statistically significant elevations in cortisol and prolactin. GH response was greater with GHRP-2 than hexarelin at the doses tested.
Limitation: Very small sample (n=8), single-dose pharmacology study only. No body composition, long-term safety, or repeated-dosing outcomes measured.
Effects of growth hormone-releasing peptide-2 in normal adults and patients with growth hormone deficiency or excess
Finding: GHRP-2 stimulated significant GH release in healthy adults and GH-deficient patients. GH-deficient patients responded robustly, supporting its diagnostic utility. Patients with acromegaly showed blunted response. Demonstrates the dose-response relationship and receptor mechanism in humans.
Limitation: Small sample across three heterogeneous groups. Not designed to assess long-term body composition or safety outcomes.
Synergistic effects of GHRH and GHRP-2 on GH release in humans
Finding: Combining GHRH (growth hormone-releasing hormone) with GHRP-2 produced synergistic GH release significantly greater than either compound alone — establishing the pharmacological rationale for stacking GHRH analogs (like CJC-1295) with GHRPs (like GHRP-2 or ipamorelin).
Limitation: Acute study — single injection combination, not a sustained protocol. Effects measured over 2 hours only.
Best for
What to expect
Realistic timeline based on available research. Individual results vary.
Minutes 15–45
Acute GH pulse peaks 15–30 minutes after subcutaneous injection, confirmed in human pharmacology studies. This is the active window per dose.
Week 1–4
With consistent use (2–3x daily), sustained elevation in average GH levels. Some users notice improved sleep quality and recovery. IGF-1 begins to rise measurably.
Month 2–4
Body composition changes (if occurring) become detectable in this window with training and adequate nutrition. Cortisol and prolactin should be monitored to ensure they remain in range.
Month 4+
Typically cycled with 4-week breaks to prevent receptor desensitization and manage the cortisol/prolactin side effect profile. Long-term continuous use is not established as safe.
Safety notes & concerns
Full safety guide →- ⚠not FDA-approved for any therapeutic indication
- ⚠raises cortisol and prolactin beyond baseline — unlike the cleaner ipamorelin, these off-target hormonal effects require monitoring
- ⚠no large human efficacy trials for performance or body composition outcomes
- ⚠unregulated supply chain — purity and peptide authenticity not guaranteed without third-party testing
- ⚠potential for GH-related side effects with sustained use: fluid retention, joint pain, insulin resistance at high doses
- ⚠cortisol elevation can be counterproductive for recovery and body composition goals if sustained
Pairs well with
Use caution with
Frequently asked questions
What is the difference between GHRP-2 and GHRP-6?
Both are synthetic GHRPs that bind the ghrelin receptor to trigger GH release. GHRP-2 (second-generation) produces higher peak GH output and causes less appetite stimulation than GHRP-6 (first-generation). GHRP-6 has deeper research on cardioprotective and gastroprotective properties due to its longer history in the literature. For GH maximization with controlled appetite, GHRP-2 is typically preferred.
How is GHRP-2 different from ipamorelin?
Ipamorelin is the most selective GHRP — it stimulates GH release without meaningful increases in cortisol, prolactin, or appetite. GHRP-2 produces stronger GH pulses but raises cortisol and prolactin to a moderate degree. Ipamorelin is considered the "cleaner" choice; GHRP-2 the "more potent" choice. Neither is more evidenced in humans — both lack large clinical trials for body composition outcomes.
What is the pralmorelin stimulation test?
Pralmorelin (the clinical name for GHRP-2) is used in some countries, particularly Japan, as a diagnostic test for growth hormone deficiency. A standardized dose is injected and GH is measured at intervals — a blunted GH response suggests GH deficiency. This clinical use provides meaningful human pharmacology data on GHRP-2's GH-stimulating effects, though the diagnostic context differs from performance use.
Should I use GHRP-2 or CJC-1295 with Ipamorelin?
These operate differently. CJC-1295 is a GHRH analog that extends GH pulse duration; Ipamorelin is a GHRP that triggers GH pulse amplitude. The CJC-1295 + Ipamorelin stack is one of the most widely used GH secretagogue combinations because the two mechanisms are synergistic. GHRP-2 could replace ipamorelin in such a stack for a stronger GH pulse at the cost of more cortisol and prolactin elevation. Most clinicians prefer ipamorelin for its cleaner profile.
Related fitness peptides
experimental recovery protocols under medical supervision
those exploring growth hormone optimization under medical supervision
those exploring GH optimization under medical supervision
understanding GH secretagogue research — use under medical supervision only
Take the Peptide Quiz
Get personalized recommendations
Stack Builder
Build a routine with GHRP-2
Last updated: 2026-05-13
Medical Disclaimer
The information on this site is for educational and informational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, or prevent any condition. Always consult with a qualified healthcare professional before starting any new supplement, peptide, or treatment protocol.